• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Tagrisso (Osimertinib)- AstraZeneca’s non-small cell lung cancer drug backed off by The National Institute of Health and Care Excellence (NICE)

Tagrisso does not meet the criteria set up by NICE’s to be considered as a life-extending treatment.

Data suggest that patients who take Tagrisso live longer than their peers who receive Roche’s Tarceva (erlotinib) or AstraZeneca’s own Iressa (gefitinib). However, AstraZeneca was not able to share any information from a randomized clinical trial comparing Tagrisso to Boehringer Ingelheim’s Gilotrif (afatinib) which is the first choice, EGFR tyrosine kinase inhibitor and this may prove to be more effective than the products used in the Tagrisso clinical trials.

 AstraZeneca’s efforts to grow sales of Tagrisso is facing a huge challenge but rising demand in market mean the drug is still well positioned. Tagrisso sales in 2019 came in at $2.3bn in about first nine months, up more than 80% over the same period of the 2018.

For more information, please contact [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

Contact
+91 9643310025, 9643312749
© 2024 Pharmintel